BioMarin Pharmaceutical Inc. (VIE:BMRN)

Market Cap	9.25B -26.0%
Revenue (ttm)	2.74B +12.9%
Net Income	297.16M -18.3%
EPS	1.54 -18.2%
Shares Out	n/a
PE Ratio	31.11
Forward PE	9.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	26
Open	48.86
Previous Close	48.91
Day's Range	48.24 - 48.93
52-Week Range	44.02 - 63.68
Beta	n/a
RSI	45.01
Earnings Date	Apr 24, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 3,221
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: BMRN

Financial Performance

In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.

Financial numbers in USD